Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

Table 1 Summary of patient populations

		Inclusion criteria			Patients contributing to pooled analysis, n
Study	Duration^*	Age, y	HbA_1c, %	eGFR,	PBO	CANA	CANA	Total	Aged
				mL/min/1.73 m²	PBO	100 mg	300 mg	Total	≥65 y
Monotherapy	26 weeks	≥18 to ≤80	≥7.0 and ≤10.0	≥50	192	195	197	584	118
Add-on to MET	26 weeks	≥18 to ≤80	≥7.0 and ≤10.5	≥55	183	368	367	918	149
Add-on to MET + SU	26 weeks	≥18 to ≤80	≥7.0 and ≤10.5	≥55	156	157	156	469	85
Add-on to MET + PIO	26 weeks	≥18 to ≤80	≥7.0 and ≤10.5	≥55	115	113	114	342	93
Overall total, n					646	833	834	2,313	445

eGFR, estimated glomerular filtration rate; PBO, placebo; CANA, canagliflozin; MET, metformin; SU, sulphonylurea; PIO, pioglitazone.
*Assessment time point; mean treatment exposure of 24.2, 24.3, and 23.8 weeks with canagliflozin 100 and 300 mg and placebo, respectively.

ISSN: 1472-6823